Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 281

1.

Novel heart failure biomarkers: why do we fail to exploit their potential?

Piek A, Du W, de Boer RA, Silljé HHW.

Crit Rev Clin Lab Sci. 2018 Apr 17:1-18. doi: 10.1080/10408363.2018.1460576. [Epub ahead of print]

PMID:
29663841
2.

Myocardial fibrosis as an early feature in phospholamban p.Arg14del mutation carriers: phenotypic insights from cardiovascular magnetic resonance imaging.

Te Rijdt WP, Ten Sande JN, Gorter TM, van der Zwaag PA, van Rijsingen IA, Boekholdt SM, van Tintelen JP, van Haelst PL, Planken RN, de Boer RA, Suurmeijer AJH, van Veldhuisen DJ, Wilde AAM, Willems TP, van Dessel PFHM, van den Berg MP.

Eur Heart J Cardiovasc Imaging. 2018 Apr 6. doi: 10.1093/ehjci/jey047. [Epub ahead of print]

PMID:
29635323
3.

Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology.

Seferović PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, Paulus WJ, Komajda M, Cosentino F, de Boer RA, Farmakis D, Doehner W, Lambrinou E, Lopatin Y, Piepoli MF, Theodorakis MJ, Wiggers H, Lekakis J, Mebazaa A, Mamas MA, Tschöpe C, Hoes AW, Seferović JP, Logue J, McDonagh T, Riley JP, Milinković I, Polovina M, van Veldhuisen DJ, Lainscak M, Maggioni AP, Ruschitzka F, McMurray JJV.

Eur J Heart Fail. 2018 Mar 8. doi: 10.1002/ejhf.1170. [Epub ahead of print] Review.

PMID:
29520964
4.

Heart transplantation in the Netherlands : A national achievement.

Damman K, Brügemann J, De Boer RA, Erasmus ME, van den Broek SAJ.

Neth Heart J. 2018 Apr;26(4):223-224. doi: 10.1007/s12471-018-1090-8. No abstract available.

5.

Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function.

Hoes MF, Grote Beverborg N, Kijlstra JD, Kuipers J, Swinkels DW, Giepmans BNG, Rodenburg RJ, van Veldhuisen DJ, de Boer RA, van der Meer P.

Eur J Heart Fail. 2018 Feb 27. doi: 10.1002/ejhf.1154. [Epub ahead of print]

PMID:
29484788
6.

Proenkephalin and risk of developing chronic kidney disease: the Prevention of Renal and Vascular End-stage Disease study.

Kieneker LM, Hartmann O, Bergmann A, de Boer RA, Gansevoort RT, Joosten MM, Struck J, Bakker SJL.

Biomarkers. 2018 Mar 8:1-9. doi: 10.1080/1354750X.2018.1443514. [Epub ahead of print]

PMID:
29466891
7.

Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge.

Ameri P, Canepa M, Anker MS, Belenkov Y, Bergler-Klein J, Cohen-Solal A, Farmakis D, López-Fernández T, Lainscak M, Pudil R, Ruschitska F, Seferovic P, Filippatos G, Coats A, Suter T, Von Haehling S, Ciardiello F, de Boer RA, Lyon AR, Tocchetti CG; Heart Failure Association Cardio-Oncology Study Group of the European Society of Cardiology.

Eur J Heart Fail. 2018 Feb 21. doi: 10.1002/ejhf.1165. [Epub ahead of print] Review.

PMID:
29464808
8.

The Failing Heart Stimulates Tumor Growth by Circulating Factors.

Meijers WC, Maglione M, Bakker SJL, Oberhuber R, Kieneker LM, de Jong S, Haubner BJ, Nagengast WB, Lyon AR, van der Vegt B, van Veldhuisen DJ, Westenbrink BD, van der Meer P, Silljé HHW, de Boer RA.

Circulation. 2018 Feb 19. pii: CIRCULATIONAHA.117.030816. doi: 10.1161/CIRCULATIONAHA.117.030816. [Epub ahead of print]

PMID:
29459363
9.

Definition of Iron Deficiency Based on the Gold Standard of Bone Marrow Iron Staining in Heart Failure Patients.

Grote Beverborg N, Klip IT, Meijers WC, Voors AA, Vegter EL, van der Wal HH, Swinkels DW, van Pelt J, Mulder AB, Bulstra SK, Vellenga E, Mariani MA, de Boer RA, van Veldhuisen DJ, van der Meer P.

Circ Heart Fail. 2018 Feb;11(2):e004519. doi: 10.1161/CIRCHEARTFAILURE.117.004519.

PMID:
29382661
10.

N-terminal pro-B-type natriuretic peptide and prognosis in Caucasian vs. Asian patients with heart failure.

Tromp J, Richards AM, Tay WT, Teng TK, Yeo PSD, Sim D, Jaufeerally F, Leong G, Ong HY, Ling LH, van Veldhuisen DJ, Jaarsma T, Voors AA, van der Meer P, de Boer RA, Lam CSP.

ESC Heart Fail. 2018 Apr;5(2):279-287. doi: 10.1002/ehf2.12252. Epub 2018 Jan 30.

11.

Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update.

Suthahar N, Meijers WC, Silljé HHW, Ho JE, Liu FT, de Boer RA.

Theranostics. 2018 Jan 1;8(3):593-609. doi: 10.7150/thno.22196. eCollection 2018. Review.

12.

Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis.

Aimo A, Januzzi JL Jr, Vergaro G, Ripoli A, Latini R, Masson S, Magnoli M, Anand IS, Cohn JN, Tavazzi L, Tognoni G, Gravning J, Ueland T, Nymo SH, Brunner-La Rocca HP, Bayes-Genis A, Lupón J, de Boer RA, Yoshihisa A, Takeishi Y, Egstrup M, Gustafsson I, Gaggin HK, Eggers KM, Huber K, Tentzeris I, Tang WHW, Grodin J, Passino C, Emdin M.

Circulation. 2018 Jan 16;137(3):286-297. doi: 10.1161/CIRCULATIONAHA.117.031560. Review.

PMID:
29335288
13.

Association of Cardiovascular Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction.

de Boer RA, Nayor M, deFilippi CR, Enserro D, Bhambhani V, Kizer JR, Blaha MJ, Brouwers FP, Cushman M, Lima JAC, Bahrami H, van der Harst P, Wang TJ, Gansevoort RT, Fox CS, Gaggin HK, Kop WJ, Liu K, Vasan RS, Psaty BM, Lee DS, Hillege HL, Bartz TM, Benjamin EJ, Chan C, Allison M, Gardin JM, Januzzi JL Jr, Shah SJ, Levy D, Herrington DM, Larson MG, van Gilst WH, Gottdiener JS, Bertoni AG, Ho JE.

JAMA Cardiol. 2018 Mar 1;3(3):215-224. doi: 10.1001/jamacardio.2017.4987.

PMID:
29322198
14.

Myocardial oedema and congestive heart failure: one piece of the puzzle? Reply.

Gorter TM, de Boer RA.

Eur J Heart Fail. 2018 Apr;20(4):827-828. doi: 10.1002/ejhf.1136. Epub 2018 Jan 10. No abstract available.

PMID:
29319924
15.

Proteomic diversity of high-density lipoprotein explains its association with clinical outcome in patients with heart failure.

Emmens JE, Jones DJL, Cao TH, Chan DCS, Romaine SPR, Quinn PA, Anker SD, Cleland JG, Dickstein K, Filippatos G, Hillege HL, Lang CC, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Zwinderman AH, Metra M, de Boer RA, Voors AA, Ng LL.

Eur J Heart Fail. 2018 Feb;20(2):260-267. doi: 10.1002/ejhf.1101. Epub 2017 Dec 18.

PMID:
29251807
16.

Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines.

Ramos IC, Versteegh MM, de Boer RA, Koenders JMA, Linssen GCM, Meeder JG, Rutten-van Mölken MPMH.

Value Health. 2017 Dec;20(10):1260-1269. doi: 10.1016/j.jval.2017.05.013. Epub 2017 Jun 20.

PMID:
29241885
17.

Predictors and outcomes of heart failure with mid-range ejection fraction.

Bhambhani V, Kizer JR, Lima JAC, van der Harst P, Bahrami H, Nayor M, de Filippi CR, Enserro D, Blaha MJ, Cushman M, Wang TJ, Gansevoort RT, Fox CS, Gaggin HK, Kop WJ, Liu K, Vasan RS, Psaty BM, Lee DS, Brouwers FP, Hillege HL, Bartz TM, Benjamin EJ, Chan C, Allison M, Gardin JM, Januzzi JL Jr, Levy D, Herrington DM, van Gilst WH, Bertoni AG, Larson MG, de Boer RA, Gottdiener JS, Shah SJ, Ho JE.

Eur J Heart Fail. 2018 Apr;20(4):651-659. doi: 10.1002/ejhf.1091. Epub 2017 Dec 11.

PMID:
29226491
18.

Prognostic Value of Serial Galectin-3 Measurements in Patients With Acute Heart Failure.

van Vark LC, Lesman-Leegte I, Baart SJ, Postmus D, Pinto YM, de Boer RA, Asselbergs FW, Wajon EMCJ, Orsel JG, Boersma E, Hillege HL, Akkerhuis KM; TRIUMPH (Translational Initiative on Unique and Novel Strategies for Management of Patients with Heart Failure) Investigators.

J Am Heart Assoc. 2017 Nov 29;6(12). pii: e003700. doi: 10.1161/JAHA.116.003700.

19.

Galectin-3 in Heart Failure: An Update of the Last 3 Years.

Gehlken C, Suthahar N, Meijers WC, de Boer RA.

Heart Fail Clin. 2018 Jan;14(1):75-92. doi: 10.1016/j.hfc.2017.08.009. Review.

PMID:
29153203
20.

An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology.

Lourenço AP, Leite-Moreira AF, Balligand JL, Bauersachs J, Dawson D, de Boer RA, de Windt LJ, Falcão-Pires I, Fontes-Carvalho R, Franz S, Giacca M, Hilfiker-Kleiner D, Hirsch E, Maack C, Mayr M, Pieske B, Thum T, Tocchetti CG, Brutsaert DL, Heymans S.

Eur J Heart Fail. 2018 Feb;20(2):216-227. doi: 10.1002/ejhf.1059. Epub 2017 Nov 16. Review.

PMID:
29148148
21.

Accumulation of 5-oxoproline in myocardial dysfunction and the protective effects of OPLAH.

van der Pol A, Gil A, Silljé HHW, Tromp J, Ovchinnikova ES, Vreeswijk-Baudoin I, Hoes M, Domian IJ, van de Sluis B, van Deursen JM, Voors AA, van Veldhuisen DJ, van Gilst WH, Berezikov E, van der Harst P, de Boer RA, Bischoff R, van der Meer P.

Sci Transl Med. 2017 Nov 8;9(415). pii: eaam8574. doi: 10.1126/scitranslmed.aam8574.

PMID:
29118264
22.

Heart failure and inflammation-related biomarkers as predictors of new-onset diabetes in the general population.

Suthahar N, Meijers WC, Brouwers FP, Heerspink HJL, Gansevoort RT, van der Harst P, Bakker SJL, de Boer RA.

Int J Cardiol. 2018 Jan 1;250:188-194. doi: 10.1016/j.ijcard.2017.10.035. Epub 2017 Oct 16.

23.

Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology.

Gorter TM, van Veldhuisen DJ, Bauersachs J, Borlaug BA, Celutkiene J, Coats AJS, Crespo-Leiro MG, Guazzi M, Harjola VP, Heymans S, Hill L, Lainscak M, Lam CSP, Lund LH, Lyon AR, Mebazaa A, Mueller C, Paulus WJ, Pieske B, Piepoli MF, Ruschitzka F, Rutten FH, Seferovic PM, Solomon SD, Shah SJ, Triposkiadis F, Wachter R, Tschöpe C, de Boer RA.

Eur J Heart Fail. 2018 Jan;20(1):16-37. doi: 10.1002/ejhf.1029. Epub 2017 Oct 16. Review.

PMID:
29044932
24.

New Blood Pressure-Associated Loci Identified in Meta-Analyses of 475 000 Individuals.

Kraja AT, Cook JP, Warren HR, Surendran P, Liu C, Evangelou E, Manning AK, Grarup N, Drenos F, Sim X, Smith AV, Amin N, Blakemore AIF, Bork-Jensen J, Brandslund I, Farmaki AE, Fava C, Ferreira T, Herzig KH, Giri A, Giulianini F, Grove ML, Guo X, Harris SE, Have CT, Havulinna AS, Zhang H, Jørgensen ME, Käräjämäki A, Kooperberg C, Linneberg A, Little L, Liu Y, Bonnycastle LL, Lu Y, Mägi R, Mahajan A, Malerba G, Marioni RE, Mei H, Menni C, Morrison AC, Padmanabhan S, Palmas W, Poveda A, Rauramaa R, Rayner NW, Riaz M, Rice K, Richard MA, Smith JA, Southam L, Stančáková A, Stirrups KE, Tragante V, Tuomi T, Tzoulaki I, Varga TV, Weiss S, Yiorkas AM, Young R, Zhang W, Barnes MR, Cabrera CP, Gao H, Boehnke M, Boerwinkle E, Chambers JC, Connell JM, Christensen CK, de Boer RA, Deary IJ, Dedoussis G, Deloukas P, Dominiczak AF, Dörr M, Joehanes R, Edwards TL, Esko T, Fornage M, Franceschini N, Franks PW, Gambaro G, Groop L, Hallmans G, Hansen T, Hayward C, Heikki O, Ingelsson E, Tuomilehto J, Jarvelin MR, Kardia SLR, Karpe F, Kooner JS, Lakka TA, Langenberg C, Lind L, Loos RJF, Laakso M, McCarthy MI, Melander O, Mohlke KL, Morris AP, Palmer CNA, Pedersen O, Polasek O, Poulter NR, Province MA, Psaty BM, Ridker PM, Rotter JI, Rudan I, Salomaa V, Samani NJ, Sever PJ, Skaaby T, Stafford JM, Starr JM, van der Harst P, van der Meer P; Understanding Society Scientific Group, van Duijn CM, Vergnaud AC, Gudnason V, Wareham NJ, Wilson JG, Willer CJ, Witte DR, Zeggini E, Saleheen D, Butterworth AS, Danesh J, Asselbergs FW, Wain LV, Ehret GB, Chasman DI, Caulfield MJ, Elliott P, Lindgren CM, Levy D, Newton-Cheh C, Munroe PB, Howson JMM; CHARGE EXOME BP, CHD Exome+, Exome BP, GoT2D:T2DGenes Consortia, The UK Biobank Cardio-Metabolic Traits Consortium Blood Pressure Working Group†.

Circ Cardiovasc Genet. 2017 Oct;10(5). pii: e001778. doi: 10.1161/CIRCGENETICS.117.001778.

PMID:
29030403
25.

The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology.

van Bilsen M, Patel HC, Bauersachs J, Böhm M, Borggrefe M, Brutsaert D, Coats AJS, de Boer RA, de Keulenaer GW, Filippatos GS, Floras J, Grassi G, Jankowska EA, Kornet L, Lunde IG, Maack C, Mahfoud F, Pollesello P, Ponikowski P, Ruschitzka F, Sabbah HN, Schultz HD, Seferovic P, Slart RHJA, Taggart P, Tocchetti CG, Van Laake LW, Zannad F, Heymans S, Lyon AR.

Eur J Heart Fail. 2017 Nov;19(11):1361-1378. doi: 10.1002/ejhf.921. Epub 2017 Sep 26.

PMID:
28949064
26.

Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology.

Corrà U, Agostoni PG, Anker SD, Coats AJS, Crespo Leiro MG, de Boer RA, Hairola VP, Hill L, Lainscak M, Lund LH, Metra M, Ponikowski P, Riley J, Seferović PM, Piepoli MF.

Eur J Heart Fail. 2018 Jan;20(1):3-15. doi: 10.1002/ejhf.979. Epub 2017 Sep 18. Review.

PMID:
28925073
27.

Plasma calcidiol, calcitriol, and parathyroid hormone and risk of new onset heart failure in a population-based cohort study.

Meems LMG, Brouwers FP, Joosten MM, Lambers Heerspink HJ, de Zeeuw D, Bakker SJL, Gansevoort RT, van Gilst WH, van der Harst P, de Boer RA.

ESC Heart Fail. 2016 Sep;3(3):189-197. doi: 10.1002/ehf2.12089. Epub 2016 Apr 26.

PMID:
28834664
28.

Vitamin D supplementation in heart failure: case closed?

de Boer RA, Meems LMG, van Veldhuisen DJ.

Eur Heart J. 2017 Aug 1;38(29):2287-2289. doi: 10.1093/eurheartj/ehx341. No abstract available.

PMID:
28810714
29.

Plasma Proenkephalin and Poor Long-Term Outcome in Renal Transplant Recipients.

Kieneker LM, Hartmann O, Struck J, Bergmann A, Gansevoort RT, Joosten MM, van den Berg E, de Boer RA, Bakker SJL.

Transplant Direct. 2017 Jul 7;3(8):e190. doi: 10.1097/TXD.0000000000000700. eCollection 2017 Aug.

30.

Phospholamban immunostaining is a highly sensitive and specific method for diagnosing phospholamban p.Arg14del cardiomyopathy.

Te Rijdt WP, van der Klooster ZJ, Hoorntje ET, Jongbloed JDH, van der Zwaag PA, Asselbergs FW, Dooijes D, de Boer RA, van Tintelen JP, van den Berg MP, Vink A, Suurmeijer AJH.

Cardiovasc Pathol. 2017 Sep - Oct;30:23-26. doi: 10.1016/j.carpath.2017.05.004. Epub 2017 May 30.

31.

Early Anti-inflammatory and Pro-angiogenic Myocardial Effects of Intravenous Serelaxin Infusion for 72 H in an Experimental Rat Model of Acute Myocardial Infarction.

Sanchez-Mas J, Lax A, Asensio-Lopez MC, Lencina M, Fernandez-Del Palacio MJ, Soriano-Filiu A, de Boer RA, Pascual-Figal DA.

J Cardiovasc Transl Res. 2017 Dec;10(5-6):460-469. doi: 10.1007/s12265-017-9761-1. Epub 2017 Jul 17.

PMID:
28718055
32.

From Inflammation to Fibrosis-Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities.

Suthahar N, Meijers WC, Silljé HHW, de Boer RA.

Curr Heart Fail Rep. 2017 Aug;14(4):235-250. doi: 10.1007/s11897-017-0343-y. Review.

33.

Exercise and heart failure: Improve your functional status and your biomarker profile.

Meijers WC, de Boer RA.

Eur J Prev Cardiol. 2017 Sep;24(13):1358-1359. doi: 10.1177/2047487317714849. Epub 2017 Jun 20. No abstract available.

PMID:
28631932
34.

Heart failure: Macrophages take centre stage in the heart-brain-kidney axis.

Silljé HHW, de Boer RA.

Nat Rev Nephrol. 2017 Jul;13(7):388-390. doi: 10.1038/nrneph.2017.73. Epub 2017 May 30. No abstract available.

PMID:
28555651
35.

Rodent heart failure models do not reflect the human circulating microRNA signature in heart failure.

Vegter EL, Ovchinnikova ES, Silljé HHW, Meems LMG, van der Pol A, van der Velde AR, Berezikov E, Voors AA, de Boer RA, van der Meer P.

PLoS One. 2017 May 5;12(5):e0177242. doi: 10.1371/journal.pone.0177242. eCollection 2017.

36.

Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association.

Chow SL, Maisel AS, Anand I, Bozkurt B, de Boer RA, Felker GM, Fonarow GC, Greenberg B, Januzzi JL Jr, Kiernan MS, Liu PP, Wang TJ, Yancy CW, Zile MR; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology; Council on Basic Cardiovascular Sciences; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Epidemiology and Prevention; Council on Functional Genomics and Translational Biology; and Council on Quality of Care and Outcomes Research.

Circulation. 2017 May 30;135(22):e1054-e1091. doi: 10.1161/CIR.0000000000000490. Epub 2017 Apr 26. Review. Erratum in: Circulation. 2017 Nov 7;136(19):e345.

PMID:
28446515
37.

Plasma galectin-3 concentrations in patients with primary aldosteronism.

van den Berg TNAD, Meijers WC, Donders ART, Van Herwaarden AE, Rongen GA, de Boer RA, Deinum J, Riksen NP.

J Hypertens. 2017 Sep;35(9):1849-1856. doi: 10.1097/HJH.0000000000001383.

PMID:
28403043
38.

New developments in the pharmacotherapeutic management of heart failure in elderly patients: concerns and considerations.

Screever EM, Meijers WC, van Veldhuisen DJ, de Boer RA.

Expert Opin Pharmacother. 2017 May;18(7):645-655. doi: 10.1080/14656566.2017.1316377. Epub 2017 Apr 17. Review.

PMID:
28375036
39.

Pulmonary arterial hypertension in congenital heart disease: translational opportunities to study the reversibility of pulmonary vascular disease.

van der Feen DE, Bartelds B, de Boer RA, Berger RMF.

Eur Heart J. 2017 Jul 7;38(26):2034-2041. doi: 10.1093/eurheartj/ehx034.

PMID:
28369399
40.

Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction.

Tromp J, Khan MA, Klip IT, Meyer S, de Boer RA, Jaarsma T, Hillege H, van Veldhuisen DJ, van der Meer P, Voors AA.

J Am Heart Assoc. 2017 Mar 30;6(4). pii: e003989. doi: 10.1161/JAHA.116.003989.

41.

Plasma potassium, diuretic use and risk of developing chronic kidney disease in a predominantly White population.

Kieneker LM, Eisenga MF, Joosten MM, de Boer RA, Gansevoort RT, Kootstra-Ros JE, Navis G, Bakker SJ.

PLoS One. 2017 Mar 27;12(3):e0174686. doi: 10.1371/journal.pone.0174686. eCollection 2017.

42.

Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure.

Aimo A, Vergaro G, Ripoli A, Bayes-Genis A, Pascual Figal DA, de Boer RA, Lassus J, Mebazaa A, Gayat E, Breidthardt T, Sabti Z, Mueller C, Brunner-La Rocca HP, Tang WH, Grodin JL, Zhang Y, Bettencourt P, Maisel AS, Passino C, Januzzi JL, Emdin M.

JACC Heart Fail. 2017 Apr;5(4):287-296. doi: 10.1016/j.jchf.2016.12.016. Epub 2017 Feb 8.

43.

Awareness of atrial fibrogenesis and natriuretic peptide release.

Meijers WC, Jaarsma T, van Veldhuisen DJ, Hoekstra T, de Boer RA.

Neth Heart J. 2017 Mar;25(3):225-226. doi: 10.1007/s12471-017-0955-6. No abstract available.

44.

Plasma N-terminal Prosomatostatin and Risk of Incident Cardiovascular Disease and All-Cause Mortality in a Prospective Observational Cohort: the PREVEND Study.

Abbasi A, Kieneker LM, Corpeleijn E, Gansevoort RT, Gans RO, Struck J, de Boer RA, Hillege HL, Stolk RP, Navis G, Bakker SJ.

Clin Chem. 2017 Jan;63(1):278-287. doi: 10.1373/clinchem.2016.259275. Epub 2016 Oct 25.

45.

Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Association With Exercise Capacity, Left Ventricular Filling Pressures, Natriuretic Peptides, and Left Atrial Volume.

Lam CS, Rienstra M, Tay WT, Liu LC, Hummel YM, van der Meer P, de Boer RA, Van Gelder IC, van Veldhuisen DJ, Voors AA, Hoendermis ES.

JACC Heart Fail. 2017 Feb;5(2):92-98. doi: 10.1016/j.jchf.2016.10.005. Epub 2016 Dec 21.

46.

Inhibition of Interleukin-6 Receptor in a Murine Model of Myocardial Ischemia-Reperfusion.

Hartman MH, Vreeswijk-Baudoin I, Groot HE, van de Kolk KW, de Boer RA, Mateo Leach I, Vliegenthart R, Sillje HH, van der Harst P.

PLoS One. 2016 Dec 9;11(12):e0167195. doi: 10.1371/journal.pone.0167195. eCollection 2016.

47.

The fate of sulfate in chronic heart failure.

Koning AM, Meijers WC, Minović I, Post A, Feelisch M, Pasch A, Leuvenink HG, de Boer RA, Bakker SJ, van Goor H.

Am J Physiol Heart Circ Physiol. 2017 Mar 1;312(3):H415-H421. doi: 10.1152/ajpheart.00645.2016. Epub 2016 Dec 6.

48.

Follow-up care by a genetic counsellor for relatives at risk for cardiomyopathies is cost-saving and well-appreciated: a randomised comparison.

Nieuwhof K, Birnie E, van den Berg MP, de Boer RA, van Haelst PL, van Tintelen JP, van Langen IM.

Eur J Hum Genet. 2017 Feb;25(2):169-175. doi: 10.1038/ejhg.2016.155. Epub 2016 Nov 30.

49.

Selecting heart failure patients for metabolic interventions.

Booij HG, Koning AM, van Goor H, de Boer RA, Westenbrink BD.

Expert Rev Mol Diagn. 2017 Feb;17(2):141-152. doi: 10.1080/14737159.2017.1266939. Epub 2016 Dec 28.

PMID:
27900885
50.

The LifeLines Cohort Study: Prevalence and treatment of cardiovascular disease and risk factors.

van der Ende MY, Hartman MH, Hagemeijer Y, Meems LM, de Vries HS, Stolk RP, de Boer RA, Sijtsma A, van der Meer P, Rienstra M, van der Harst P.

Int J Cardiol. 2017 Feb 1;228:495-500. doi: 10.1016/j.ijcard.2016.11.061. Epub 2016 Nov 11.

Supplemental Content

Loading ...
Support Center